The resource provides a look at protein localization patterns across the proteome as well as responses to events like alternative splicing and drug perturbation.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
Researchers at the University of Copenhagen used mass spectrometry to analyze dental plaque from 21 individuals recovered from a medieval Danish gravesite.
Agena has an ongoing partnership with Guangzhou-based DaRui to develop MassArray-based diagnostics for cancer and inherited diseases for the Chinese market.
The company's revenues were up, but fell short of Wall Street estimates as growth in the European market was hampered by lower sales to pharma customers there.
The approach could be particularly useful for harmonizing data from large multi-site efforts as proteomics experiments continue to grow in size and complexity.
A preliminary analysis based on high-resolution metabolomics pointed to three blood plasma metabolites with apparent ties to active, pulmonary tuberculosis.
The tool allows users to search for unexpected modifications and other phenomena that are difficult to identify using conventional mass spec search software.
A team from the EPFL has identified the chemical NTCB as a potential digestion reagent for middle-down work, though bioinformatic hurdles still remain.
The agreement is part of a larger effort by the company to apply its Signabody affinity reagents to toxicity biomarker work and other areas of drug development.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
